← back to search

Chihiro Shimazaki

Kyoto Medical Center · JP
Area of research
Hematology · Genetics
Research interest
Research interests include Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research, and Hematopoietic Stem Cell Transplantation.
h-index
39
citations
7,107
works
397
NIH funding
primary concept
Medicine
email

Recent publications

The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
2024cited by 2position: contributordoi
The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis.
2023cited by 0position: contributordoi
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
New England Journal of Medicine 2021cited by 641position: middledoi
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
The Lancet 2019cited by 631position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 2 papers (2023–2024)Shin‐ichi Fuchida · Springer Nature2 papers (2023–2024)Tomoki Ito · Springer Nature1 papers (2024–2024)Yasuhiro Tanaka · 神鋼記念病院1 papers (2024–2024)Satoru Kosugi · Toyonaka Municipal Hospital1 papers (2024–2024)Yuji Shimura · MDPI1 papers (2024–2024)Yutaka Shimazu · Kyoto University1 papers (2024–2024)Mitsuhiro Matsuda · PL Byoin1 papers (2024–2024) · 1 papers (2024–2024)Itaru Matsumura · Kindai University Hospital1 papers (2024–2024)Yoshiyuki Onda · Kyoto University1 papers (2024–2024)Junya Kanda · Japan Advanced Institute of Science and Technology1 papers (2024–2024)